TCR-T Cell Therapy Platforms

The core technology of our company was developed by Prof. Dr. Ulrike Protzer, Director of the Institute of Virology, Munich University of Technology, Germany, and has been exclusively licensed to us for product development and clinical research. Products include the world's leading hepatitis B virus-specific TCR-T cell therapy technologies for diseases and cancers caused by hepatitis B virus infection, as well as for HPV/EBV. Different from traditional cell therapy, hepatitis B virus-specific TCR-T cell therapy target viral antigens rather than patient autoantigens, avoiding off-target toxicity of targeting normal tissues, and effectively reducing side effects caused by attacking non-target tissues.

T Cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes

T Cells Expressing a Chimeric Antigen Receptor That Binds Hepatitis B Virus Envelope Proteins Control Virus Replication in Mice

Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use

Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model

FULLY CLOSED AND AUTOMATED CELL THERAPY MANUFACTURING SYSTEM

Our proprietary cell therapy manufacturing system deploy fully closed and automated technologies to ensures high quality and consistency while lowering cost. In collaboration with Singapore Health Sciences Authority Cell Therapy Facility (HSA-CTF), the proprietary manufacturing system have been fully validated and approved by the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA).

T cell receptor grafting allows virological control of hepatitis B virus infection